STAQ Pharma

Key People

• Joe Bagan - CEO & Board Member
• Mark Spiecker - President & Board Member
• Jeff Hval - COO, Chief Pharmacist & Board Member
• David Colson - Chief Financial Officer
• Emily Reyes - Vice President Of Quality
• P. W. - Vice President Of Sales
• L. T. - Vice President Operations
• J. K. - Chief Of Staff

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.

The leadership team includes individuals with proven track records in the MedTech sector, such as CEO Joe Bagan and President Mark Spiecker, who have previously led successful ventures. This collective experience enhances the company's strategic direction and operational execution.

Clinical Need

Aspect: Very Strong
Summary: STAQ Pharma addresses critical drug shortages by providing high-quality sterile compounded medications.

By offering compounded medications in prefilled syringes for anesthesia and surgical procedures, STAQ Pharma directly addresses the pressing issue of drug shortages in healthcare settings, thereby fulfilling a vital clinical requirement.

Competition

Aspect: Somewhat crowded
Summary: The pharmaceutical compounding market has several established players, but STAQ Pharma's focus on safety and quality differentiates it.

While the market for compounded pharmaceuticals includes multiple competitors, STAQ Pharma's commitment to cGMP standards and collaboration with healthcare systems provides a competitive edge. However, the presence of other established entities necessitates continuous innovation and quality assurance.

Technical Challenge

Aspect: Predictable
Summary: The technical processes involved in compounding medications are well-established and manageable.

Compounding medications, especially in a cGMP-compliant facility, involves standardized procedures and quality controls. STAQ Pharma's investment in state-of-the-art facilities and experienced personnel ensures these processes are executed effectively.

Patent

Aspect: None
Summary: STAQ Pharma's business model does not rely on proprietary patents but on quality and service.

Unlike traditional pharmaceutical companies that depend on patented drugs, STAQ Pharma's value proposition lies in its adherence to safety, transparency, availability, and quality, which are critical in the compounding industry.

Financing

Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors, indicating strong financial health.

With total funding of $84.3 million from investors such as Rev1 Ventures and Cincinnati Children's Hospital Medical Center, STAQ Pharma is well-positioned to execute its growth strategies and enhance its market presence.

Regulatory

Aspect: 510k/PMA
Summary: STAQ Pharma operates FDA-registered facilities adhering to cGMP standards, ensuring regulatory compliance.

By maintaining FDA-registered facilities and adhering to cGMP standards, STAQ Pharma ensures the safety and efficacy of its products, which is crucial for gaining and retaining trust among healthcare providers and patients.

Opportunity Rollup

Odds of Success

4.4

Peak Market Share

6.05

Segment CAGR

5.4%

Market Segment

Pharmaceutical Compounding

Market Sub Segment

503B Outsourcing Facilities

Key Takeaway

STAQ Pharma's strategic focus on quality and safety positions it well to address critical drug shortages, despite a competitive market landscape.